Sanofi-Aventis - Biotech, Pharma and Life Science Channel
Sanofi-Aventis is a global pharmaceutical company with annual sales of $40,871m, placing it the second highest in the world.
Although Sanofi-Aventis products are for a a very wide range of health problems, their major products are those for diabetes, oncology and thrombosis. Lantus® is the main insulin product in the global market, with annual sales exceeding $4.8m. Other major prescription drugs produced by Sanofi-Aventis are Lovenox®, Taxotere®, Plavix®, Aprovel®, Eloxatin®, and Multaq®.
Sanofi Pasteur is the vaccine division of this company, and is helping lead this area of health care, with the production of Polio, Pertussis, influenza and travel vaccines. There is also a veterinary group within Sanofi-Aventis.
Source; BioPortfolio.com and Sanofi-Aventis.com
Add the Sanofi-Aventis News Channel to your RSS reader;
Follow the Sanofi-Aventis Twitter feed;
News Articles
CHICAGO, May 16, 2013 /PRNewswire/ -- Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...
BRIDGEWATER, N.J., May 16, 2013 /PRNewswire/ -- Professional football icon Jerome Bettis and Sanofi US, the makers of Auvi-Q™ (epinephrine injection, USP), have teamed up to raise awareness abou...
PatientsLikeMe and the nonprofit Center for Information and Study on Clinical Research Participation (CISCRP) announce a new partnership with global healthcare leader Sanof...
Second Annual BioNJ Diagnostics & Personalized Medicine Innovation Summit Taking Place at Sanofi
Life Science Industry Leaders and Innovator Companies Meet to Network and Identify Partnership Opportunities that Advance Personalized Medicine BioNJ, the trade associa...
Low-risk aortic valve patients are maintained with aspirin and clopidogrel only On-X® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the...
Connie Wierman is New Theorem Vice President of Biopharmaceutical Development
Connie Wierman, a seasoned executive with more than 25 years of biopharmaceutical experience, has been named vice president of biopharmaceutical development for Theorem Cli...
Alliance Boots builds up interest in China - comment from The Economist Intelligence Unit
“Alliance Boots is building up its interests in China's pharmacy sector, in anticipation of growth and consolidation in the market. The Economist Intelligence Unit expects pharma sales (in...
Date: 5th & 6th June 2013 Locations: Grand Hôtel Suisse-Majestic (Montreux – Switzerland) This year, The European Pricing & Profit Optimisation forum on Life Sciences boas...
Regeneron Acquires Full Rights to Two Novel Ophthalmology Development Programs
TARRYTOWN, N.Y., May 3, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it has expanded its ophthalmology portfolio by acquiring full exclusive rights to...
Sanofi: Q1 2013 business EPS(1) impacted by exclusivity losses in prior year
PARIS, May 2, 2013 /PRNewswire/ -- Sanofi (NYSE: SNY; EURONEXT: SAN) Q1 2013 Change
Events
Strategic Pipeline Planning & Portfolio Valuation
R&D Target Selection, Licensing and M&A, Prioritization and Investment Decision-Making
Pharmaceutical Regulatory Affairs in Africa
Pharmaceutical Regulatory Affairs in Africa
3rd Annual Advancing Clinical Research in Turkey, the Middle East & North Africa
With little growth in the traditional regions of North America and Western Europe, industry sponsored clinical trials are increasingly conducted in emerging regions.
Companies
Zalicus focuses its internal drug development efforts on pain and immuno-inflammatory diseases. Our pipeline for pain includes Exalgo⢠(hydromorphone HCl) extended-release ta...
Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Pa...
Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals t...
Bionest Partners Inc. provides strategy consulting services exclusively for the life science industries to help pharmaceutical, biopharmaceutical, diagnostics, biotechnology, and...
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forwardâs products and services have been utilized in o...
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other s...
GENFIT (Paris:ALGFT) is a biopharmaceutical company focused on the Discovery and Development of drug candidates in strategic therapeutic fields linked to cardiometabolic and neuro...
Phase Forward is a leading provider of integrated data management solutions for clinical trials and drug safety. Phase Forward's products and services have been utilized in over 1...
Dossia is a non-profit organization consisting of several large U.S. employers who have united under a common vision: to empower their employees to make smarter more informed deci...
sanofi-aventis is committed to protecting the privacy of visitors. Your email and its content will be used to provide you with an answer to your message. We will not send you any unsolicited materials...
Clinical Trials
Open-Label Study of H5 Vaccine in Participants of Protocol 04-077
This study may provide safety information on a flu vaccine given to children and may provide immunogenicity information to add to what was collected in a previous flu vaccine study. Partic...
Immunogenicity and Safety of Tetraxim Versus Local DTP + IPV
The present clinical study will assess the immunogenicity and reactogenicity of Sanofi Pasteur's DTaP-IPV combined vaccines as a three-dose primary vaccination at 2, 4 and 6 months of age...
Assessment of Cardioversion Using Transesophageal Echocardiography II (ACUTE II)
SPECIFIC AIM: To test the safety and feasibility of using low molecular weight heparin (LMWH, enoxaparin sodium; Lovenox, Sanofi-Aventis) in lieu of unfractionated heparin (UFH) as antith...
Immunogenicity and Safety of Pentaxim™ in an Indian Population
The present clinical study will assess the immunogenicity as the primary objective and the reactogenicity as the secondary objective of Aventis Pasteur's DTacP-IPV// PRP~T combined vaccine...
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
The present clinical study will assess the immunogenicity and reactogenicity of the subsequent administration of Aventis Pasteur's DTacP-IPV//PRP~T combined vaccine (PENTAVAC™/PENTAXIM),...
Revaccination With Subunit Influenza A/Vietnam/1203/2004 (H5N1) Vaccine
The purpose of this study is to determine whether having received an H5 vaccine in the past primes the immune system to respond rapidly to another dose of H5 vaccine. One hundred seventeen...
Evaluate the immunological memory induced by 4 doses of GSK Biologicals' 11valent pneumococcal vaccine; study antibody persistence 30 months after the 4 dose vaccination with GSK Biologica...
"The aims of this trial are to demonstrate the consistency of three manufacturing lots of GSK Biologicals' DTaP-IPV candidate vaccine in terms of immunogenicity and to evaluate non-inferio...
The study seeks to define, with precision, the safety and efficacy of APSV, two dose potencies of one lot in vaccinia-naive adults. The ability of this vaccine to induce a classic �ta...
Vaccine for Prevention of Bird Flu
Study Design: This is a Phase I, randomized, open-label study to evaluate the safety, tolerability, and immunogenicity of four vaccination regimens against the influenza virus hemagglutin...
PubMed Articles
OBJECTIVE: Aflibercept (Zaltrap(®)) is a novel antiangiogenic agent that binds to vascular endothelial growth factor (VEGF) and inhibits VEGF-dependent tumor growth. We aimed to characterize the popu...
Multi-regional clinical trials have been widely used for efficient global new drug developments. Both a fixed-effect model and a random-effect model can be used for trial design and data analysis of a...
AIMS/HYPOTHESIS: In vitro, insulin glargine (A21Gly,B31Arg,B32Arg human insulin) has an insulin receptor (IR) profile similar to that of human insulin, but a slightly higher affinity for the IGF-1 rec...
Verorab™ was licensed in 1985 for both pre- and post-exposure prophylaxis of rabies. The next generation purified Vero cell rabies vaccine (PVRV-NG) is a highly purified vaccine. We performed a phas...
National shortage of purified-protein derivative tuberculin products.
Tubersol, a product of Sanofi Pasteur Limited, is in short supply nationwide until at least the end of May 2013. Tubersol is one of two purified-protein derivative (PPD) tuberculin products licensed b...
Abstract Objective: Human papillomavirus (HPV) has an important role in the aetiology of a range of diseases, including cervical, other anogenital, and head and neck cancers, genital warts and recurre...
Starting from 11β-HSD1 inhibitors that were active ex vivo but with Cyp 3A4 liability, we obtained a new series of adamantane ureas displaying potent inhibition of both human and rodent 11β-HSD1 enz...
The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer of cabazitaxel (Jevtana(®), sanofi-aventis, UK) to submit evidence of its clinical and cost effectiveness for...
Lixisenatide: First Global Approval.
The selective once-daily prandial glucagon-like peptide-1 (GLP-1) receptor agonist lixisenatide (Lyxumia(®)) is under development with Sanofi for the treatment of type 2 diabetes mellitus. Lixisenati...
The use of either a polyampholyte buffer or a simple buffer system for the high-performance cation-exchange chromatofocusing of monoclonal antibodies is demonstrated for the case where the pH gradient...
